Clinical trial NCT00126191 (phase 2, status: terminated)
Conditions: burkitt lymphoma, non-hodgkins lymphoma, atypical burkitt lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate, leucovorin, ifosfamide, etoposide, cytarabine, mesna
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, OS(=O)(=O)CCS
Reason stopped: 
    closed due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented Burkitt or atypical Burkitt according to World Health
             Organization (WHO) criteria.

          -  Pathology must be reviewed at the Brigham and Women's Hospital (BWH).

          -  Measurable or evaluable disease: Disease reproducibly measurable in two perpendicular
             dimensions on exam, computed tomography (CT), radiograph, or magnetic resonance
             imaging (MRI). Disease present on bone marrow biopsy will be considered as evaluable
             disease.

          -  The following may not be used as the sole site of measurable or evaluable disease:
             *ascites, *pleural effusion, *bone lesion or *central nervous system (CNS) disease.

          -  Age > 18

          -  Laboratory data (within 2 weeks of study registration):

               -  ANC > 1500/ul;

               -  platelet > 100,000/ul;

               -  creatinine < 1.5 X normal;

               -  creatinine clearance > 60 ml/min;

               -  bilirubin < 1.5 X normal;

               -  AST and ALT < 2.5 X normal;

               -  alkaline phosphates < 3 X normal;

               -  HIV negative;

               -  cardiac ejection fraction > 50%.

        Exclusion Criteria:

          -  Previous chemotherapy or radiation therapy. Steroids of less than 72 hours duration
             for impending oncologic emergency are allowed.

          -  Uncontrolled bacterial, fungal, or viral infection.

          -  Concomitant malignancy excluding carcinoma in situ of the cervix and basal cell
             carcinoma of the skin.

          -  Serious comorbid disease. Clinically significant pulmonary symptomatology. In patients
             with a history of symptomatic pulmonary disease, pulmonary function tests (PFTs)
             should document an forced expiratory volume at 1 second (FeV1), forced vital capacity
             (FVC), and total lung capacity (TLC) of > 60% predicted and carbon monoxide diffusing
             capacity of the lung (DLCO) of > 50% predicted. No clinically significant cardiac
             symptomatology. The cardiac ejection fraction must be > 50%.

          -  Pregnancy. All males and females with reproductive potential must consent to use an
             effective form of contraception while on study.

          -  Major surgery within the previous 2 weeks.